JP2004521108A5 - - Google Patents

Download PDF

Info

Publication number
JP2004521108A5
JP2004521108A5 JP2002558467A JP2002558467A JP2004521108A5 JP 2004521108 A5 JP2004521108 A5 JP 2004521108A5 JP 2002558467 A JP2002558467 A JP 2002558467A JP 2002558467 A JP2002558467 A JP 2002558467A JP 2004521108 A5 JP2004521108 A5 JP 2004521108A5
Authority
JP
Japan
Prior art keywords
peptide
test compound
composition
δpkc
absence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002558467A
Other languages
English (en)
Japanese (ja)
Other versions
JP4115838B2 (ja
JP2004521108A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/047556 external-priority patent/WO2002057413A2/en
Publication of JP2004521108A publication Critical patent/JP2004521108A/ja
Publication of JP2004521108A5 publication Critical patent/JP2004521108A5/ja
Application granted granted Critical
Publication of JP4115838B2 publication Critical patent/JP4115838B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002558467A 2001-01-18 2001-11-09 δＰＫＣの活性化および阻害のためのペプチド Expired - Fee Related JP4115838B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26206001P 2001-01-18 2001-01-18
PCT/US2001/047556 WO2002057413A2 (en) 2001-01-18 2001-11-09 Peptides for activation and inhibition of delta pkc

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008048806A Division JP4592772B2 (ja) 2001-01-18 2008-02-28 δＰＫＣの活性化および阻害のためのペプチド

Publications (3)

Publication Number Publication Date
JP2004521108A JP2004521108A (ja) 2004-07-15
JP2004521108A5 true JP2004521108A5 (enExample) 2006-01-05
JP4115838B2 JP4115838B2 (ja) 2008-07-09

Family

ID=22995990

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002558467A Expired - Fee Related JP4115838B2 (ja) 2001-01-18 2001-11-09 δＰＫＣの活性化および阻害のためのペプチド
JP2008048806A Expired - Fee Related JP4592772B2 (ja) 2001-01-18 2008-02-28 δＰＫＣの活性化および阻害のためのペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008048806A Expired - Fee Related JP4592772B2 (ja) 2001-01-18 2008-02-28 δＰＫＣの活性化および阻害のためのペプチド

Country Status (6)

Country Link
US (5) US6855693B2 (enExample)
EP (2) EP1351980B1 (enExample)
JP (2) JP4115838B2 (enExample)
AU (1) AU2002226061B2 (enExample)
CA (1) CA2434643C (enExample)
WO (1) WO2002057413A2 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168354A1 (en) * 2000-11-10 2002-11-14 Daria Mochly-Rosen psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia
EP1351980B1 (en) * 2001-01-18 2014-12-31 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
CA2481512C (en) 2002-04-22 2013-06-18 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase c.gamma. for pain management
EP1578365A4 (en) * 2002-11-14 2009-09-23 Arbor Vita Corp MOLECULAR INTERACTIONS IN NEURONS
US20110002978A1 (en) 2003-06-17 2011-01-06 Harrison Roger G Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof
WO2005027959A1 (en) * 2003-09-24 2005-03-31 Institut Pasteur Selective inhibition of nf-kappab activation by peptides designed to disrupt nemo oligomerization.
US7560241B2 (en) * 2003-12-09 2009-07-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating mitochondrial aldehyde dehydrogenase-2
WO2005065666A1 (en) * 2003-12-22 2005-07-21 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Us of a pkc-delta inhibitor for the inhibition of metastatic melanoma
WO2005107789A1 (en) * 2004-04-30 2005-11-17 The Board Of Trustees Of The Leland Stanford Junior University Use of delta pkc peptides for modulation of reactive oxigen species
EP1784483A2 (en) * 2004-08-02 2007-05-16 The Board Of Trustees Of The Leland Stanford Junior University Peptide sequence for modulation of delta protein kinase c
US7265092B2 (en) 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
US20060148700A1 (en) * 2004-11-10 2006-07-06 Daria Mochly-Rosen Methods and compositions for reducing injury to a transplanted organ
CN101111257A (zh) * 2005-01-04 2008-01-23 里兰斯坦福初级大学理事会 增加脑血流量的方法
US20060160062A1 (en) * 2005-01-14 2006-07-20 Young Lindon H Perfusion and/or preservation solution for organs
US20090186814A1 (en) * 2005-01-26 2009-07-23 Fumiaki Ikeno Methods and Compositions for Reducing Ischemia-Derived Microvascular Damage
WO2006095086A2 (fr) * 2005-03-07 2006-09-14 Laurence Faure Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence.
US20070066526A1 (en) * 2005-09-02 2007-03-22 Daria Mochly-Rosen Method for reducing risk of and extent of injury due to stroke in hypertensive subjects
EP1934338A2 (en) 2005-09-19 2008-06-25 Kai Pharmaceuticals, Inc. Protein kinase c peptide modulators of angiogenesis
DK2056851T3 (da) * 2005-12-09 2013-10-14 Philadelphia College Of Osteopathic Medicine Organkonservering og/eller -perfusion
US20070148628A1 (en) * 2005-12-09 2007-06-28 Philadelphia College Of Osteopathic Medicine Organ preservation and/or perfusion
JP2010505841A (ja) 2006-10-02 2010-02-25 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー εＰＫＣのＣ２ドメイン由来のペプチドおよびその利用方法
CN103961686A (zh) * 2006-11-16 2014-08-06 凯制药公司 用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽
WO2008080153A2 (en) * 2006-12-22 2008-07-03 The Children's Hospital Of Philadelphia A novel protein kinase c therapy for the treatment of acute lung injury
US20080293640A1 (en) * 2007-01-10 2008-11-27 Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of Polypeptide inhibitors of HSP27 kinase and uses therefor
EP2606903B1 (en) * 2007-01-10 2016-09-14 Purdue Research Foundation Polypeptide inhibitors of HSP27 kinase and uses therefor
AU2008206077A1 (en) 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
US20090062208A1 (en) * 2007-02-06 2009-03-05 Mochly-Rosen Daria D Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-PKC inhibitor
KR100906153B1 (ko) 2007-07-04 2009-07-03 재단법인 한국원자력의학원 프로테인 카이네즈 씨 활성 저해용 단백질 및 이를포함하는 약제학적 조성물
ES2547229T3 (es) 2007-08-07 2015-10-02 Purdue Research Foundation Inhibidores de cinasa y usos de los mismos
AU2008293496A1 (en) * 2007-08-27 2009-03-05 Kai Pharmaceuticals, Inc. Protein kinase C-delta inhibitors that protect against cellular injury and inflammation and promote astrocyte proliferation
WO2009065080A1 (en) * 2007-11-16 2009-05-22 San Diego State University Research Foundation Compositions and method for manipulating pim-1 activity in circulatory system cells
US20090318351A1 (en) * 2008-03-12 2009-12-24 Kevin Grimes Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist
US20100048482A1 (en) * 2008-08-15 2010-02-25 Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating epsilon protein kinase c-mediated cytoprotection
CN102316731B (zh) 2008-12-10 2016-06-01 普渡研究基金会 基于细胞渗透性肽的激酶抑制剂
US9890195B2 (en) * 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
SG10201406921SA (en) 2009-07-29 2014-11-27 Kai Pharmaceuticals Inc Therapeutic agents for reducing parathyroid hormone levels
EP2942060A1 (en) 2009-09-29 2015-11-11 Joslin Diabetes Center, Inc. Use of Protein Kinase C Delta (PKCD) Inhibitors to Treat Diabetes, Obesity and, Hepatic Steatosis
WO2012170955A1 (en) 2011-06-08 2012-12-13 Kai Pharmaceuticals, Inc. Therapeutic agents for regulating serum phosphorus
US9217137B2 (en) 2011-08-12 2015-12-22 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for specific regulation of pyruvate dehydrogenase kinase
US9452218B2 (en) 2012-03-09 2016-09-27 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
KR101611494B1 (ko) 2012-12-20 2016-04-12 한양대학교 산학협력단 ＰＫＣ－δ 검출용 폴리펩티드 및 이의 용도
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
CN106467493B (zh) * 2015-08-14 2021-04-23 苏州兰鼎生物制药有限公司 一种治疗缺血性脑卒中后遗症的化合物
WO2020032951A1 (en) 2018-08-09 2020-02-13 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
KR20220159945A (ko) * 2020-03-31 2022-12-05 도레이 카부시키가이샤 화상 해석 장치, 화상 해석 장치의 제어 방법, 화상 해석 시스템, 및 화상 해석 시스템의 제어 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) * 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5783405A (en) 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
US5935803A (en) * 1994-02-01 1999-08-10 Terrapin Technologies, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
US5776716A (en) * 1994-02-01 1998-07-07 Terrapin Technologies, Inc. Methods for identifying agents which block the interaction of fyn with PKC-theta, and uses thereof
US5519003A (en) 1994-02-01 1996-05-21 Board Of Trustees Of The Leland Stanford Junior University WD-40-derived peptides and uses thereof
US6165977A (en) 1996-10-18 2000-12-26 Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase C methods and compositions
US6228843B1 (en) * 1999-04-23 2001-05-08 University Technology Corporation Method of using PKC inhibiting compounds to treat vascular disease
US6664040B2 (en) 2000-05-23 2003-12-16 The Regents Of The University Of California Compositions and methods for delivery of a molecule into a cell
EP1351980B1 (en) * 2001-01-18 2014-12-31 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
US7224668B1 (en) * 2002-11-27 2007-05-29 Cisco Technology, Inc. Control plane security and traffic flow management
US7265092B2 (en) 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
US20060148700A1 (en) * 2004-11-10 2006-07-06 Daria Mochly-Rosen Methods and compositions for reducing injury to a transplanted organ
CN101111257A (zh) * 2005-01-04 2008-01-23 里兰斯坦福初级大学理事会 增加脑血流量的方法
US20090186814A1 (en) * 2005-01-26 2009-07-23 Fumiaki Ikeno Methods and Compositions for Reducing Ischemia-Derived Microvascular Damage
US20090062208A1 (en) * 2007-02-06 2009-03-05 Mochly-Rosen Daria D Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-PKC inhibitor
AU2008293496A1 (en) 2007-08-27 2009-03-05 Kai Pharmaceuticals, Inc. Protein kinase C-delta inhibitors that protect against cellular injury and inflammation and promote astrocyte proliferation

Similar Documents

Publication Publication Date Title
JP2004521108A5 (enExample)
CA2434643A1 (en) Peptides for activation and inhibition of.delta.pkc
CA2361716A1 (en) Method of preparing alkylated salicylamides
EP2261248A3 (en) KDR peptides and vaccines comprising the same
JP2004000251A5 (enExample)
JP2005516885A5 (enExample)
EP0333174A3 (en) Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
JP2007518818A5 (enExample)
CZ40198A3 (cs) Derivát opioidního peptidu, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje
WO1999060013A3 (en) Il-6 antagonist peptides
JP2007529204A5 (enExample)
JP2006501165A5 (enExample)
CA2391333A1 (en) Sustained release formulation of a peptide and a copolymer
JP2004521123A5 (enExample)
JP2006523214A5 (enExample)
JP2010513327A5 (enExample)
JP2009535410A5 (enExample)
JP2003501010A5 (enExample)
WO2001028576A3 (en) NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
JP2000001439A5 (enExample)
EP1609861A4 (en) ION CHANNEL ACTIVITY INHIBITABLE LOW-MOLECULAR PEPTIDES
JP2005515981A5 (enExample)
JP2008508363A5 (enExample)
WO2002047719A3 (en) Survical promoting ncam binding and ncam ligand biding compounds
KR930703348A (ko) 인자 Ⅱ에이(Ⅱa) 억제제